| Document |
Document Title |
|
WO/2020/045247A1 |
A heterocycle-containing amino acid compound represented by general formula (1) or a salt thereof. (In the formula, R1 and R2 may be the same or different and represent a hydrogen atom or a protective group of a carboxyl group, R3 repres...
|
|
WO/2020/043831A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compound...
|
|
WO/2020/045856A1 |
The present invention relates to a novel hypoxia-inducible factor 1α (HIF-1α) inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as...
|
|
WO/2020/038405A1 |
Provided are a preparation method of pyrrolo-amino-pyridazinone compound and an intermediate thereof. The reaction conditions are easy to control, the processing following the reaction is simple, the production rate is high, and the meth...
|
|
WO/2020/040614A1 |
The present invention provides: a preparation method for a (3R,5R)-7-[2-(4-flurophenyl)-5-isopropyl-3-phenyl-4-[(4-hydr
oxymethylphenylamino)carbonyl]-pyrrrol-1-yl]-3,5-dihydroxy heptanoic acid hemicalcium salt; an intermediate used ther...
|
|
WO/2020/037231A1 |
Gold compounds and pharmaceutically acceptable salts thereof are disclosed. Certain compounds and salts are active as antibacterial, antifungal, and/or anti-parasitic agents. The disclosure provides pharmaceutical compositions containing...
|
|
WO/2020/035464A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...
|
|
WO/2020/035027A1 |
Provided are a linker represented by formula I or I', an antibody-drug conjugate including the same, a use thereof, a pharmaceutical composition including the antibody-drug conjugate, and a use of the antibody-drug conjugate in treating ...
|
|
WO/2020/035825A1 |
The present invention disclosed novel phenylamidine compounds of formula (I), wherein, Cy, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and m have the same meanings as defined in the description.The present invention further discloses a proce...
|
|
WO/2020/029591A1 |
Provided is a L-pyroglutamic acid metal complex having a structure represented by formula (I), which falls within the technical field of pesticides. The L-pyroglutamic acid metal complex having the structure represented by formula (I) pr...
|
|
WO/2020/027304A1 |
Provided are carotenoid derivatives having exceptional hydrophilicity and oral absorptivity. A carotenoid-related compound represented by the formula (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are ...
|
|
WO/2020/025789A1 |
The present invention relates to salts of elafibranor.
|
|
WO/2020/023333A1 |
The present disclosure provides compounds and compositions capable of treating cancer or an autoimmune disease, such as Crohn's disease, and methods of use thereof.
|
|
WO/2020/022134A1 |
A compound represented by formula (I). (In the formula, each of R1-R4 independently represents a hydrogen atom or an optionally substituted monovalent hydrocarbon group having 1-6 carbon atoms; each of T1 and T2 independently represents ...
|
|
WO/2020/023794A1 |
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
|
|
WO/2020/016903A1 |
The present invention relates to improved process for the preparation of a pyrrole derivative as a racemic mixture, an enantiomer, a diastereoisomer, a mixture thereof, a tautomer thereof or a pharmaceutically acceptable salt and hydrate...
|
|
WO/2020/016427A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
|
WO/2020/017569A1 |
The purpose of the present invention is to provide a novel T-type calcium channel blocker. A compound represented by general formula (I), a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof or a solvate...
|
|
WO/2020/012339A1 |
The invention is directed to substituted carbon-linked bicycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (X): (X) wherein C', D', L2', L3', R1', R2', R3', R4', R5', R6', R7', R8', z1', z...
|
|
WO/2020/011922A1 |
The present invention relates to certain dithiocarbamate compounds of formula (I) comprising a nitrogen containing heterocyclic ring, and exhibiting strong absorption in the visible range of the light spectrum. The compounds of the inven...
|
|
WO/2020/012305A1 |
The following invention relates to (R)-4-(1-(1-(4-(trifluoromethyl)benzyl) pyrrodiline- 2-carboxamide) cyclopropyl benzoic acid (Compound 1) or a salt thereof. Advantageous methods for obtaining the Compound 1 are also described, as well...
|
|
WO/2020/014304A1 |
Compositions of furan based surfactants derived from unsaturated carbon-containing molecules, such as fatty acids, as well as methods for forming furan based surfactants from unsaturated carbon-containing molecules, such as fatty acids, ...
|
|
WO/2020/009016A1 |
The present invention provides a method for producing an organic compound in which functional groups are reacted with each other without the use of a solvent. The present invention pertains to a method for producing an organic compound c...
|
|
WO/2020/010155A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/006224A1 |
Provided herein are compounds (e.g., compounds of Formula (I) and Formula (II), that modulate HCN channels, intermembrane proteins that serve as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells....
|
|
WO/2020/004537A1 |
Provided is a heterocyclic compound that has orexin-2 type receptor agonistic activity. A compound represented by formula (I) [wherein each symbol is as defined in the description] or a salt thereof has orexin-2 type receptor agonistic a...
|
|
WO/2020/006384A1 |
Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase ("MMP") inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid a...
|
|
WO/2020/006269A1 |
The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
|
|
WO/2019/244694A1 |
Provided is a curable compound having a low melting temperature, having excellent workability as a result of having good solvent solubility, and being capable of forming a cured product having hyperthermostability. This curable compoun...
|
|
WO/2019/242192A1 |
The present invention relates to a brivaracetam intermediate, a preparation method therefor, and a preparation method for brivaracetam. The steps of the method for preparing brivaracetam described in the present invention are short and t...
|
|
WO/2019/242780A1 |
Intermediates used for preparing brivaracetam, preparation methods for the intermediates, and a use. The present invention comprises an intermediate compound A and an intermediate compound B, preparation methods therefor, and a synthetic...
|
|
WO/2019/246352A1 |
Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical...
|
|
WO/2019/242692A1 |
The present application provides a compound in formula III, and further provides a use of the compound in the synthesis of a Brivaracetam intermediate and a crude drug, and a synthesis method. A raw material involved in the method of the...
|
|
WO/2019/245287A1 |
The present invention relates to a modified polymerization initiator and a preparation method therefor, wherein the modified polymerization initiator can bear various intramolecular functional groups by comprising a unit derived from a c...
|
|
WO/2019/241292A1 |
Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
|
|
WO/2019/241567A1 |
The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related ...
|
|
WO/2019/241739A1 |
Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeuti...
|
|
WO/2019/232664A1 |
A sulfonyl substituted furan compound having anti-inflammatory immune activity and a derivative thereof, represented by the following formula (I):. The compound and a derivative thereof have anti-inflammatory immune activity.
|
|
WO/2019/232708A1 |
The present invention relates to a method for preparing pregabalin by a biological enzyme method. In particular, the method comprises producing pregabalin B and an R-configuration compound C by using a compound A as a raw material under ...
|
|
WO/2019/233904A1 |
The invention relates to organic electroluminescence devices containing indone carbazole derivatives.
|
|
WO/2019/236957A1 |
Provided herein are small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) activity, and methods of use thereof for the treatment of disease, including leukemia and other cancers, as well as other diseases dependent on the act...
|
|
WO/2019/229239A1 |
A compound of formula (I) wherein: M is selected from Mo or W; X is selected from O or NR5; R1 and R2 are independently selected from H, C1-6 alkyl, and aryl; C1-6 alkyl and aryl optionally being substituted with one or more of C1-6 alky...
|
|
WO/2019/226991A1 |
Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imag...
|
|
WO/2019/220293A1 |
Described herein is a perfluorinated aminoolefin compound of general formula (I): CFY=CXN(Rf)CF2Rf' where: (a) Rf and Rf' are (i) independently selected from a linear or branched perfluoroalkyl group having 1-8 carbon atoms, optionally c...
|
|
WO/2019/221122A1 |
The present invention addresses the problem of providing a compound having a β-lactamase inhibitory activity. The problem is solved by a compound which is represented by general formula (1) that represents a compound in which a specific...
|
|
WO/2019/221641A1 |
The invention relates to medical chemistry, specifically to new biologically active compounds - amide derivatives of prostaglandin F2 alpha. Said compounds have low cytotoxicity and are able to stimulate the formation of endogenous nitri...
|
|
WO/2019/220125A1 |
This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections.More specifically, the com...
|
|
WO/2019/222105A1 |
A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20 –(Z)b–(Y)c–(R21)a–(X)d–R22–R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted...
|
|
WO/2019/217890A1 |
Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5- hydroxytryptamine receptor 7 activi...
|
|
WO/2019/215022A1 |
The présent invention is related to a method for nucleating crystals from a solution comprising the steps of: injecting in a first capillary (1) tube an under saturated solution comprising a solvent and a soluble compound to be crystall...
|
